Beta Glucan and Lactobacillus rhamnosus Heriz I

This is a combination of a soluble dietary fiber (beta glucan) and a specific probiotic strain (Lactobacillus rhamnosus Heriz I) that has been studied for its immunomodulatory effects, particularly in breast cancer patients undergoing chemotherapy.\n\nThe combination has been investigated in randomized, double-blind, placebo-controlled clinical trials where it showed potential benefits for immune function. In these studies, participants received two 10-mg capsules of soluble 1-3,1-6, D-beta glucan and one capsule of Lactobacillus rhamnosus strain Heriz I (2 \u00D7 10^7 CFU) daily[1][3].\n\nResearch findings indicate that this combination may:\n- Affect white blood cell counts in chemotherapy patients\n- Decrease serum levels of IL-4\n- Potentially increase serum levels of IL-12 (though not statistically significant)\n- Improve functional scales in quality of life measurements for breast cancer patients\n- Potentially reduce symptom scores in breast cancer patients undergoing chemotherapy[1][3]\n\nThe Lactobacillus rhamnosus Heriz I strain was isolated from conventional yogurt from the Heriz region and has been registered in the NCBI GeneBank[1].\n\n## Research Status\n\nThe combination has been studied in clinical trials with breast cancer patients receiving chemotherapy. A study published in 2024 suggested that this combination \"may be useful as immunomodulary supplements in chemotherapy patients however further studies were needed\"[1][5][6].\n\nAnother study published in 2020 found that the combination \"may be associated for improving functional scales and symptoms in patients with BC who underwent chemotherapy\"[3].\n\nA more recent review published in June 2024 provided \"supporting data to indicate beneficial effects of treatment with L. rhamnosus Heriz I and Beta glucan in breast cancer\"[4].\n\nWhile showing promise, the researchers consistently note that further studies are needed to fully establish the benefits of this combination.